ImmunityBio (IBRX) Competitors

ImmunityBio (NASDAQ:IBRX) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, community ranking, media sentiment and analyst recommendations.

Is IBRX or QGEN more profitable?

Qiagen has a net margin of 4.23% compared to ImmunityBio's net margin of -8,016.83%. Qiagen's return on equity of 13.92% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-8,016.83%	N/A	-110.02%
Qiagen	4.23%	13.92%	8.40%

Which has more risk & volatility, IBRX or QGEN?

ImmunityBio has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.

Do analysts prefer IBRX or QGEN?

ImmunityBio currently has a consensus price target of $12.19, indicating a potential upside of 339.98%. Qiagen has a consensus price target of $47.71, indicating a potential upside of 14.30%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities research analysts clearly believe ImmunityBio is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Qiagen	0 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.27

Does the MarketBeat Community believe in IBRX or QGEN?

Qiagen received 231 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 60.14% of users gave Qiagen an outperform vote while only 46.15% of users gave ImmunityBio an outperform vote.

Company	Underperform	Outperform
ImmunityBio	Outperform Votes 18 46.15%	Underperform Votes 21 53.85%
Qiagen	Outperform Votes 249 60.14%	Underperform Votes 165 39.86%

Do insiders & institutionals believe in IBRX or QGEN?

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 83.4% of ImmunityBio shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has better earnings and valuation, IBRX or QGEN?

Qiagen has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$14.75M	160.33	-$583.20M	-$0.63	-4.40
Qiagen	$1.98B	4.69	$83.59M	$0.36	115.94

Does the media refer more to IBRX or QGEN?

In the previous week, ImmunityBio and ImmunityBio both had 9 articles in the media. ImmunityBio's average media sentiment score of 0.59 beat Qiagen's score of 0.20 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Qiagen beats ImmunityBio on 11 of the 17 factors compared between the two stocks.